TEL AVIV, Israel, August 3, 2017 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage
pharmaceutical Company specializing in the development of
cannabinoid-based drugs, announced today that it will host a
conference call and webcast on Thursday,
August 10, 2017, to discuss results for the period ended
June 30, 2017 and to provide an
update on current developments with respect to its clinical
programs:
Conference Call & Webcast:
Thursday, August 10, 2017,
8:30 am Eastern Time / 5:30 am Pacific Time
Participant Dial-In Numbers:
Toll-Free:
+1-877-870-4263
Toll/International:
+1-412-317-0790
Webcast:
https://www.webcaster4.com/Webcast/Page/1726/22002
Replay, available until Aug 17,
2017
Replay Dial-In Numbers:
Toll-Free:
+1-877-344-7529
Toll/International:
+1-412-317-0088
Passcode:
10110882
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists, focused on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in two internal drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets
to the treatment of Tourette's syndrome; and THX-ULD01 targets the
high-value and under-served market of mild cognitive impairments.
Please visit our website for more information
at www.therapixbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements about the
Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss our search for a U.S. based Chief Executive
Officer. These forward-looking statements involve certain risks and
uncertainties, including, among others, risks that could cause the
Company's results to differ materially from those expected by
Company management or otherwise described in or implied by the
statements in this press release. Any forward-looking statement in
this press release speaks only as of the date of this press
release. The Company undertakes no obligation to publicly update or
review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by any applicable securities laws. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in Therapix
Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is
available on the SEC's website, www.sec.gov.
For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences,
josh@therapixbio.com
View original
content:http://www.prnewswire.com/news-releases/therapix-biosciences-second-quarter-2017-conference-call-and-webcast-scheduled-for-thursday-august-10-2017-300498696.html
SOURCE Therapix Biosciences Ltd